<DOC>
	<DOCNO>NCT02151513</DOCNO>
	<brief_summary>The purpose study examine change immune function , measure biomarkers blood , happen intrathecal ( spinal ) delivery opioid medication treatment moderate severe cancer pain . Hypothesis : Treatment pain intrathecal ( spinal ) therapy associate little alteration immune function measure biomarkers blood cancer patient moderate severe pain .</brief_summary>
	<brief_title>Pilot Study Effect Intrathecal Opioids Immune Function Humans With Cancer Pain</brief_title>
	<detailed_description>Biomarkers immune function measure patient receive intrathecal pain pump management cancer pain .</detailed_description>
	<criteria>Diagnosis cancer Evaluation pain management physician confirmation cancer primary etiology patient 's pain Moderate severe pain , specify baseline Pain Rating Score 5 scale 0 ( pain ) 10 ( bad pain imaginable ) despite current opioid therapy Pain management plan ( developed Interventional Pain Service , patient primary service ) include placement intrathecal drug delivery system pain management Able willing give inform consent Patients expect life expectancy le 12 week Patients felt safe surgical candidate pain management physician placement intrathecal drug delivery system ( IDDS ) due presence severe medical comorbidities Patients candidate intrathecal drug therapy due coagulopathy , concurrent necessary use blood thinner , presence systemic infection , drug allergy analgesic agent , evidence CSF obstruction technical factor Severe untreated psychiatric disease Refusal inform consent Pregnant patient patient le 18 year age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Cancer-associated pain</keyword>
	<keyword>Immune function</keyword>
</DOC>